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To test the hypothesis that Merkel cell polyomavirus 
(MCPyV) can infect cells of the lymphoid system, we ana-
lyzed 353 specimens, including 152 non-Hodgkin lympho-
mas, 44 Hodgkin lymphomas, 110 benign lymph nodes, 
27 lymph nodes with metastasis, and 20 extranodal tis-
sue samples. MCPyV DNA was detected by quantitative 
PCR in 13 (6.6%) of 196 lymphomas, including 5 (20.8%) 
of 24 chronic lymphocytic leukemia specimens, and in 11 
(10%) of 110 benign lymph nodes, including 8 (13.1%) of 
61 samples of reactive hyperplasia and 3 (10.3%) of 29 nor-
mal lymph nodes. Other samples were MCPyV negative. 
Sequence analysis of 9 virus-positive samples conﬁ  rmed 
the identity of MCPyV; 3 viral strains were represented. Im-
munohistochemical testing showed that 1 T-cell lymphoma 
expressed MCPyV T-antigen. These ﬁ  ndings suggest that 
the lymphoid system plays a role in MCPyV infection and 
may be a site for MCPyV persistence.
M
erkel cell polyomavirus (MCPyV) was ﬁ  rst described 
in 2008 (1) as a new human virus associated with 
Merkel cell carcinoma (MCC), an uncommon but aggressive 
form of skin cancer. Subsequent studies have reported the 
presence of MCPyV in 24%–100% of MCCs from patients 
from the United States, Germany, France, the Netherlands, 
and Australia (1–11). Findings of the clonal integration of 
MCPyV in tumor cell genomes, tumor-associated mutations 
in the large T-antigen (T-ag) gene, and large T-ag expres-
sion in tumors suggest that MCPyV is not only associated 
with MCC, but that it may be the causative agent (1,12,13). 
However, the natural reservoir of MCPyV in infected hosts 
remains to be identiﬁ  ed. MCPyV DNA has been detected at 
low copy number in some non-MCC skin tumors, in normal 
tissues of skin and the gastrointestinal tract, and in a few 
nasopharyngeal aspirates and blood samples, including in-
ﬂ  ammatory monocytes (1,5,6,11,14–16).
Lymphocytes can disseminate viruses throughout a 
host and may provide sites of viral persistence. Human 
polyomaviruses are known to establish persistent infec-
tions in healthy persons, to undergo periodic reactivation 
and replication, and to cause disease in susceptible hosts. 
Some polyomaviruses are lymphotropic; BK virus, simian 
virus 40, and JC virus DNA sequences have been detected 
in human lymphoid tissues, blood cells, and lymphomas 
(17–20). Recently, Shuda et al. (13) reported the presence 
of MCPyV in a low percentage (2.2%) of hematolymphoid 
malignancies. In this study, we investigated the presence of 
MCPyV in benign lymph nodes and malignant lymphomas 
in patients from Canada.
Design and Methods
Patients and Samples
This study was approved by the Capital Health Re-
search Ethics Board, Halifax, Nova Scotia, Canada, and 
by the Baylor College of Medicine Institutional Review 
Board, Houston. A total of 353 frozen specimens from 
various body sites were analyzed. Tissues from 196 malig-
nant lymphomas, including 152 non-Hodgkin lymphoma 
(NHL) and 44 Hodgkin lymphoma (HL) samples, were 
retrieved from the Department of Anatomical Pathology, 
Queen Elizabeth II Health Sciences Center, Halifax, Nova 
Scotia, Canada.
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All cases were diagnosed during 1994 through 2001 
and classiﬁ   ed according to World Health Organization 
criteria by using morphologic and immunohistochemical 
evaluation (21). The NHL samples were classiﬁ  ed as B-
cell lymphoma (n = 133), NK/T-cell lymphoma (n = 18), or 
were unclassiﬁ  ed (n = 1). The HL samples were classiﬁ  ed 
as classical HL (n = 41) or nodular lymphocyte predomi-
nant HL (n = 3). Also included in our study were 157 non-
lymphoma frozen tissue specimens, including 110 benign 
lymph node biopsy specimens from healthy patients or 
patients with inﬂ  ammatory disease, 27 lymph nodes from 
patients with metastatic carcinoma or melanoma, 7 biopsy 
specimens of inﬂ  ammatory tissues, and 13 other neoplastic 
(non-MCC) tissue samples.
Lymphoma specimens were obtained from 96 wom-
en and 98 men; patients’ ages ranged from 15 to 88 years 
(mean 54.5 years). Of the 110 benign lymph nodes, 53 
were from women and 57 from men, ranging in age from 
17 to 85 years (mean 46 years). Lymph nodes with meta-
static tumors were obtained from 16 women and 10 men, 
ranging in age from 22 to 86 years (mean 60.6 years). Of 
the 7 inﬂ  ammatory tissue samples, 3 were from women 
and 4 were from men 19–84 years of age (mean 52 years). 
Finally, the non-MCC tumors were obtained from 8 men 
and 5 women, ranging in age from 22 to 72 years (mean 
50.5 years). Data were not available for 3 patients, 2 with 
lymphoma and 1 with metastatic cancer. The cancers of all 
lymphoma patients were staged according to the Ann Ar-
bor system (22). 
Formalin-ﬁ  xed, parafﬁ  n-embedded biopsy specimens 
of skin cancers (4 MCCs and 4 melanomas), obtained from 
the archives of the Department of Pathology, Baylor Col-
lege of Medicine, Houston, Texas, USA, served as controls 
for PCR. Specimens were collected during 1998–2008. 
Immunohistochemical Analysis
The expression of MCPyV T-ag was detected by im-
munohistochemical analysis by using a BenchMark XT 
IHC (Ventana Medical Systems, Inc., Tucson, AZ, USA) 
system. Tissue sections on microslides were deparafﬁ  nized 
with xylene, hydrated in serially diluted alcohol, and en-
dogenous peroxidase activity was quenched. The sections 
were then treated with slightly basic Tris-based buffer for 
30 min for antigen retrieval. Sections next were incubat-
ed with CM2B4, a monoclonal antibody against MCPyV 
large T-ag (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) at a dilution of 1:250, followed by a standard 
polymer detection kit (diaminobenzidine) that served as the 
chromogen. The slides were counterstained with hematox-
ylin, dehydrated, and mounted for examination. A sample 
from a patient with MCC served as a positive control.
DNA Extraction
DNA was extracted from frozen tissues by lysis buffer/
proteinase K treatment and phenol-chloroform extraction 
as previously described (20), omitting the deparafﬁ  niza-
tion step. For the parafﬁ  n-embedded specimens, sections 
were deparafﬁ  nized, and DNA was extracted by using our 
previously described protocol (20). During sample process-
ing, stringent precautions were taken to avoid cross-con-
tamination between samples. The microtome was cleaned 
carefully, and the blade was replaced for sectioning of each 
tissue. Other safety measures included working within a 
biosafety hood located in a dedicated room free from plas-
mids and viruses and using a dedicated set of pipettors and 
barrier ﬁ  lter tips. In addition, a negative extraction control 
that lacked tissue was processed in parallel.
Real-Time Quantitative PCR
Samples were ﬁ  rst screened for the single-copy hu-
man RNase P gene by real-time quantitative PCR (qPCR), 
as described (20,23). Brieﬂ  y, 5 μL of each DNA sample 
(undiluted and 1:10 diluted) was used in 50-μL qPCRs. 
This strategy detected potential PCR inhibitors in the DNA 
preparations, determined the human cell equivalents in 
each DNA sample, and normalized MCPyV viral loads to 
human cell numbers.
MCPyV was detected by qPCR with primers and Taq-
Man probe (Applied Biosystems, Foster City, CA, USA) 
designed to detect sequences from the unique coding re-
gion of the small tumor antigen (t-ag) gene of MCPyV. The 
sequences of the oligonucleotides were as follows: LT3-
fwd primer 5′-AGTGTTTTTGCTATCAGTGCTTTA
TTCT-3′, corresponding to nt 632–659 of MCPyV350 
(GenBank accession no. EU375803); LT3-rev primer 
5′-CCACCAGTCAAAACTTTCCCA-3′, corresponding to 
nt 702–682; and ﬂ   uorogenic probe 5′-FAM-TGGTTT
GGATTTCCTC-MGB-3′, corresponding to nt 661–676. 
The pCR.MCV350 plasmid described by Feng et al. (1) 
was used as a positive control. Ampliﬁ  cations were per-
formed with the ABI Prism 7700 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA) by using 
the following cycling parameters: 2 min at 50°C, 10 min at 
95°C, followed by 40 cycles of 15 s at 95°C and of 1 min 
at 60°C. All PCRs were performed in duplicate. Reactions 
were considered positive if >10 viral genome copies/reac-
tion were detected.
Conventional PCR
Conventional PCR was performed on a subset 
of DNA samples to validate the presence of MCPyV. 
The primer set used was the following: MC_F2 (5′-
CTCATCCTCTGGATCCAGTAGC-3′) and MC_R2 
(5′-CAGAAGAGATCCTCCCAGGTG-3′) speciﬁ  c  for 
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a conserved region between nt positions 1142 and 1267 
of the large T-ag gene of MCPyV (GenBank accession 
no. EU375803) and gave a 126-bp fragment. The pCR.
MCV350 positive control plasmid was added to the con-
trol PCR outside the clean room after tubes containing 
test DNAs and negative controls (without DNA template) 
were closed. PCRs were performed in a GeneAmp PCR 
System 2700 thermal cycler (Applied Biosystems). Ther-
mal cycling parameters were as follows: 94°C for 2 min, 
followed by 45 cycles at 94°C for 15 s, 60°C for 15 s, and 
72°C for 15 s, with a ﬁ  nal extension step at 72°C for 7 min. 
Ampliﬁ  ed fragments were visualized by electrophoresis on 
a 3% agarose gel and stained with ethidium bromide. All 
PCR products were then puriﬁ  ed by using the DNA Clean 
& Concentrator-5 system (Zymo Research, Orange, CA, 
USA) and sequenced by Lone Star Labs, Inc. (Houston, 
TX, USA).
Statistical Analysis
The z score of difference for proportions was used to 
test for a difference between selected groups and an out-
come. Fisher exact test was used to test the distribution of 
clinical stage of disease and 5-year survival category be-
tween MCPyV-status groups; a p value <0.05 was consid-
ered signiﬁ  cant.
Results
DNA Recoveries
DNA was extracted from the specimens and screened 
for suitability for qPCR analysis by ampliﬁ  cation of the 
cellular RNase P gene. Serial dilutions were tested to de-
termine whether PCR inhibitors were present in the DNA 
samples and to select noninhibitory dilutions for MCPyV 
analysis. Total DNA yields ranged from 41 × 104 to 403 × 
106 cell equivalents (median 51 × 106) for the lymphoma 
samples, from 64 × 103 to 216 × 106 cell equivalents (me-
dian 29 × 106) for the benign lymph node samples, from 
13 × 105 to 117 × 106 cell equivalents (median 21 × 106) 
for the lymph node samples with metastatic cancer, from 
30 × 105 to 78 × 106 cell equivalents (median 39 × 106) 
for the other inﬂ  ammatory tissues, and from 16 × 105 to 
126 × 106 cell equivalents (median 20 × 106) for the other 
neoplastic tissues.
MCPyV Detection in MCC
We tested 4 MCC and 4 melanoma samples (ﬁ  xed and 
parafﬁ  n-embedded) for the presence of MCPyV by qPCR. 
MCPyV sequences were detected in 2 of 4 MCC samples; 
none were detected in the 4 melanoma samples (Table 1). 
MCCs contained an average of 0.29 (range 0.02–0.56) 
MCPyV genome copies per cell. MCPyV in 1 sample was 
conﬁ  rmed by conventional PCR and sequence analysis. The 
sequence of the ampliﬁ  ed fragment showed 98% similarity 
with the MCC350 reference sequence (GenBank accession 
no. EU375803) and 100% homology with MCC349 (Gen-
Bank accession no. FJ173813).
MCPyV Detection in Malignant Lymphomas, Lymphoid 
Tissues, and Other Inﬂ  ammatory or Neoplastic Tissues
A total of 196 frozen malignant lymphoma samples 
were tested for MCPyV sequences. The classiﬁ  cation of 
those samples is summarized in Table 2. Viral DNA was 
detected in 13 (6.6%) of the lymphomas (Tables 1, 2). As 
determined by qPCR, the viral copy numbers were relative-
ly low. An average of 4.6 copies/104 cells (range 0.16–27 
copies/104 cells, median 0.94 copies/104 cells) was detected 
in the MCPyV-positive lymphomas. Among the lympho-
mas, the overall frequency of MCPyV between NHL and 
HL cases was similar (6.6% and 6.8%; p = 1.0) (Table 2).
MCPyV was identiﬁ  ed most frequently in chronic lym-
phocytic leukemia/small lymphocytic lymphoma (CLL/
SLL) (20.8%), a tumor type known to occur in MCC pa-
tients (Table 2). Patients with CLL/SLL had a high preva-
lence of MCPyV compared to all other B-cell lymphomas 
(20.8% vs. 2.8%; p = 0.01). The virus loads in CLL/SLL 
were similar to those found in patients with other types 
of lymphoma. Characteristics of MCPyV-positive and 
MCPyV-negative CLL/SLL patients are shown in Table 3. 
None of the 24 CLL/SLL patients had MCC.
A total of 110 frozen benign lymph node samples, 
27 lymph nodes with metastatic tumors, and 20 other in-
ﬂ  ammatory or neoplastic tissues were tested in parallel 
(Table 4). Eleven of 110 (10%) benign lymph nodes were 
MCPyV positive (Tables 1, 4). Viral loads in MCPyV-
positive lymph nodes averaged 2.3 copies/104 cells (range 
0.44–6.0 copies/104 cells, median 2.1 copies/104 cells). Of 
the 11 benign lymphoid specimens positive for MCPyV 
DNA, 8 were among 61 (13.1%) reactive hyperplasia sam-
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Table 1. MCPyV DNA from lymphoid and nonlymphoid samples, 
Halifax, Nova Scotia, Canada, and from MCC tissues, Houston, 
Texas, USA, 1994–2008* 







Frozen samples from Halifax, Nova 
Scotia, Canada 
  Malignant lymphomas  196 13 (6.6) 
  Benign lymph nodes  110 11 (10.0) 
  Lymph nodes with non-MCC metastatic 
   cancer  
27 0
  Other inflammatory tissues  7 0
  Other neoplastic non-MCC tissues  13 0
 Totals  353 24  (6.8) 
Fixed tissues from Houston, Texas, USA 
 MCC  4 2  (50.0) 
 Melanoma  4 0
*MCPyV, Merkel cell polyomavirus; MCC, Merkel cell carcinoma. Lymphotropism of MCPyV, Nova Scotia, Canada
ples and 3 were from 29 (10.3%) normal lymph nodes. All 
other samples tested were negative for MCPyV (Table 4).
Sequence analysis conﬁ  rmed the qPCR results. Con-
ventional PCR with MCPyV-speciﬁ   c primers was per-
formed on 9 viral DNA-positive samples (4 lymphoma, 
5 reactive hyperplasia). DNA ampliﬁ   cation products of 
the expected size (126 bp) from the large T-ag gene were 
obtained, and sequence analysis conﬁ  rmed the identity of 
MCPyV. Three of 4 MCPyV-positive lymphoma samples 
shared 100% sequence homology with strain MCC344 
(GenBank accession no. FJ173807), whereas sequences of 
the remaining sample were identical to those of MCC349 
(GenBank accession no. FJ173813). Among the 5 MCPyV-
positive reactive hyperplasia samples, 4 had 100% homol-
ogy to strain MCC344 and 1 to strain MCC339 (GenBank 
accession no. EU375804).
Expression of MCPyV T-antigen
A series of 17 lymphoid specimens (7 of which were 
positive for MCPyV DNA by PCR), consisting of 11 lym-
phomas and 6 reactive hyperplasia samples, were tested for 
expression of MCPyV T-ag. Immunohistochemical stain-
ing with the CM2B4 monoclonal antibody was carried out 
without knowledge of the PCR results. One sample, classi-
ﬁ  ed as an angioimmunoblastic T-cell lymphoma, expressed 
detectable T-ag in scattered lymphocytes (Figure). This 
sample was positive for MCPyV DNA by PCR. The re-
maining samples tested were negative for T-ag expression 
by immunohistochemical test.
Clinical Follow-Up
Five-year clinical follow-up information was avail-
able for 114 of 196 patients who had malignant lymphoma. 
Of those patients not included in follow-up analysis, 14 
had died from other causes, 47 had received a diagnosis 
of lymphoma within the past 5 years, and 21 were lost to 
follow-up. Among the 114 patients with a 5-year follow-
up, 49 had died of the disease and 65 were alive (24 with 
lymphoma and 41 without). Analyses showed no differ-
ence in the distributions among survival categories relative 
to MCPyV status (Table 5). Of the MCPyV-positive pa-
tients for whom follow-up data were available, 3 (42.9%) 
of 7 were alive and in remission compared with 38 (35.5%) 
of 107 MCPyV-negative patients. There were 3 (42.9%) 
deaths among the MCPyV-positive group and 46 (43.0%) 
deaths among the MCPyV-negative group (p = 0.88).
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Table 2. Presence of MCPyV in malignant lymphomas, Nova Scotia, Canada, 1994–2001* 
Pathology No. samples tested No. (%) MCPyV positive
Non-Hodgkin lymphoma 152 10 (6.6)
 B-cell  lymphoma 133 8 (6.0)
    Burkitt lymphoma/Burkitt cell leukemia  2 0
    Chronic lymphocytic leukemia/small lymphocytic lymphoma 24 5 (20.8)
    Diffuse follicular center lymphoma 10
    Diffuse large B-cell lymphoma 52 0
    Diffuse large B-cell lymphoma/T-cell/histiocyte-rich type 1 0
    Extranodal marginal zone B-cell lymphoma 20
  Follicular  lymphoma 35 2 (5.7) 
  Lymphoblastic  leukemia/lymphoma 10
  Lymphoplasmacytic  lymphoma 40
  Mantle  cell  lymphoma 70
    Posttransplant lymphoproliferative disorder, polymorphic 1 0
    Splenic marginal zone lymphoma 10
  Unclassified 2 1 (50.0) 
 NK/T-cell  lymphoma 18 2 (11.0) 
    Anaplastic large cell lymphoma 8 1 (12.5) 
    Angiocentric T cell lymphoma (nasal type) 10
  Angioimmunoblastic  T-cell  lymphoma 2 1 (50.0) 
    Extranodal NK/T-cell lymphoma, nasal type 20
  Lymphoblastic  lymphoma 40
  Peripheral  T-cell  lymphoma 10
Unclassified 10
Hodgkin lymphoma 44 3 (6.8)
  Classical Hodgkin lymphoma 41 3 (7.3)
  Mixed  cellularity 10 2 (20.0)
  Nodular  sclerosis 29 1 (3.4)
  Unclassified  20
  Nodular lymphocyte predominant Hodgkin lymphoma  3 0
All 196 13 (6.6)
*MCPyV, Merkel cell polyomavirus. RESEARCH
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Table 3. MCPyV infection and characteristics of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, Nova Scotia,
Canada, 1994–2001*  
Characteristic No. (%) cases  No. (%) MCPyV positive  No. (%) MCPyV negative 
Patient sex 
  M  16 (66.7)  2 (12.5)  14 (87.5) 
  F  8 (33.3)  3 (37.5)  5 (62.5) 
Patient age, y 
 < 60 6 (25.0)  0 6 (100.0) 
  >60  18 (75.0)  5 (27.8)  13 (72.2) 
Disease stage† 
  I  9 (40.9)  1 (11.1)  8 (88.9) 
  II  5 (22.7)  3 (60.0)  2 (40.0) 
 III  0 0 0
  IV  8 (36.4)  1 (12.5)  7 (87.5) 
Patient survival‡ 
  Alive in remission  2 (15.4)  1 (50.0)  1 (50.0) 
  Alive with disease  6 (46.1)  0 6 (100.0) 
  Dead from disease  5 (38.5)  1 (20.0)  4 (80.0) 
Total 24 5 (20.8)  19 (79.2) 
*No patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had Merkel cell carcinoma. MCPyV, Merkel cell polyomavirus. 
†Stage of disease for 2 MCPyV-negative patients was unknown. 
‡Five-year follow-up survival information. Data were available for 13 patients, excluding 10 who had received a diagnosis within the past 5 y and one who 
was lost to follow-up. Disease refers to original diagnosis of either lymphoma or leukemia. 
Table 4. Presence of MCPyV in benign lymph nodes, lymph nodes with metastatic cancer, and other inflammatory or neoplastic 
tissues, Nova Scotia, Canada, 1994–2001* 
Pathologic feature  No. samples tested  No. (%) MCPyV positive 
Benign lymph nodes  110 11 (10) 
 Acute  lymphadenitis  1 0
 Atypical  hyperplasia  2 0
 Dermatopathic  lymphadenopathy  3 0
  Florid follicular hyperplasia  1 0
Mycobacterium avium–intracellulare infection  2 0
 Necrotizing  granulomas  3 0
  Normal lymph node  29 3 (10.3) 
  Reactive hyperplasia  61 8 (13.1) 
 Sarcoidosis  60
  Systemic mast cell disease  1 0
 Toxoplasmosis  10
Lymph nodes with metastatic tumors  27 0
 Carcinoma  25 0
 Melanoma  20
Other inflammatory tissues  7 0
 Chronic  sialadenitis  1 0
 Follicular  bronchiolitis  1 0
  Hemophagocytic syndrome, spleen  1 0
Helicobacter pylori–associated gastritis  1 0
 Hemochromatosis,  liver  1 0
  Hyperplasia and chronic perifolliculitis, skin  1 0
 Interstitial  pneumonitis  1 0
Other neoplastic tissues  13 0
  Mixed mullerian tumor  1 0
 Neurofibroma  10
 Sarcoma  40
 Schwannoma  20
 Thymoma  50
*MCPyV, Merkel cell polyomavirus.  Lymphotropism of MCPyV, Nova Scotia, Canada
Discussion
This study describes the presence of MCPyV DNA in 
benign lymph nodes and malignant lymphomas in speci-
mens from patients living in Canada. MCPyV was detected 
in 6.6% of lymphomas and in 10% of nonneoplastic lymph 
node samples. These results, together with those of Shuda 
et al. (13) and Mertz et al. (14), support the hypothesis 
that lymphocytes and monocytes may serve as a tissue 
reservoir for MCPyV infection. Because serologic assays 
have indicated that MCPyV primary infections frequent-
ly occur in children (24–26), we favor the interpretation 
that the MCPyV genomes detected in the adult lymphoid 
tissues reﬂ  ect the presence of persistently infected cells. 
Only 1 specimen among MCPyV DNA–positive samples 
tested expressed T-ag, which suggests that most infected 
lymphoid cells are not producing detectable levels of viral 
protein. However, because MCPyV DNA copy numbers 
in the samples were low, a few antigen-expressing cells in 
the tissues may have escaped detection in the immunohis-
tochemical assays.
The data from this study do not suggest that MCPyV 
caused the lymphoid tumors that were virus positive. How-
ever, more comprehensive studies are necessary to exclude 
the possibility that MCPyV may have lymphomagenic po-
tential under certain conditions. An observation of interest 
was the presence of MCPyV in 5 (20.8%) of 24 CLL/SLL 
cases. CLL is a type of leukemia that is now regarded as 
being identical to SLL (27). The most recent World Health 
Organization classiﬁ  cation scheme for hematopoietic ma-
lignancies considers CLL and SLL to be different mani-
festations of the same disease and combines these entities 
into 1 disease category (CLL/SLL) (21). Some studies have 
found that CLL co-exists with MCC, making the associa-
tion rare but well recognized (28–34). CLL and MCC are 
age-related with an increased risk in those >60 years of age. 
Koljonen et al. (35) recently showed that MCPyV DNA 
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Figure. Merkel cell polyomavirus (MCPyV) large T-antigen (T-ag) expression in human tissues. A) Merkel cell carcinoma stained with 
CM2B4 antibody as a positive control; MCPyV T-ag was detected. B) Expression of MCPyV T-ag in small lymphocytes in an MCPyV 
DNA–positive angioimmunoblastic T-cell lymphoma, stained with CM2B4. C) MCPyV DNA–positive reactive lymphoid hyperplasia sample 
reacted with CM2B4; no T-ag was detected. D) MCPyV DNA-negative chronic lymphocytic leukemia/small lymphocytic lymphoma sample 
stained with CM2B4; no T-ag was detected. Original magniﬁ  cation ×40.RESEARCH
is frequently present in MCCs that occur in CLL patients. 
The basis for the association between CLL and MCPyV is 
unclear. The link may be coincidental or may reﬂ  ect some 
inﬂ  uence of the MCPyV-infection process.
The present study provides evidence of the presence of 
MCPyV in samples of reactive lymphoid hyperplasia. (Re-
active lymphoid hyperplasia refers to a benign, reversible 
enlargement of the lymph node as a consequence of pro-
liferation of some or all of its cellular components.) This 
is a normal response of the lymph nodes to an antigenic 
stimulus, such as infection or inﬂ  ammation. Viruses, e.g., 
Epstein-Barr virus, induce reactivity of lymphoid cells in 
lymphoid tissues from healthy persons (36). In our study, 8 
(13.1%) of 61 reactive hyperplasia specimens were shown 
to harbor MCPyV DNA at low copy number. Whether 
MCPyV infection prompted those cases of reactive hyper-
plasia is unknown.
In conclusion, our ﬁ  ndings of the presence of MCPyV 
in malignant lymphomas, reactive hyperplasia, and normal 
lymph nodes support the hypothesis that MCPyV is lym-
photropic. Our ﬁ  ndings also suggest that the lymphoid sys-
tem plays a role in MCPyV infection and may be a site for 
MCPyV persistence.
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